Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from May 1, 2012, to October 31, 2012. The document serves as a Block Listing Six Monthly Return, detailing the status of various share option schemes and the number of unallotted securities available under these plans.
Key Financial Metrics
The filing text does not provide data regarding revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to equity compensation scheme statistics.
Material Changes in Share Option Schemes
The following changes occurred in unallotted securities across various schemes during the reporting period:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: Decreased by 4,373,486 shares (issued/allotted), resulting in a balance of 9,717,201.
- GlaxoSmithKline Share Option Plan - ADS: Increased by 10,000,000 shares (new allotment) and decreased by 7,175,490 shares (issued/allotted), resulting in a net increase and a balance of 8,362,078.
- GlaxoSmithKline Savings Related Share Option Scheme: Decreased by 115,727 shares (issued/allotted), resulting in a balance of 3,889,981.
- Other Schemes: No securities were issued or allotted under the Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, or SmithKline Beecham 1989 plans during this period. Balances remained unchanged.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or details on contingencies and unusual items.
Key Facts for Investor Verification
- Verify the total number of shares available for future issuance across all active schemes, which totals approximately 31.5 million shares as of October 31, 2012.
- Confirm the 10,000,000 share increase in the ADS scheme to understand potential future dilution.
- Note that significant issuance activity (over 11 million shares total) occurred in the Ordinary Shares and ADS plans, while legacy schemes remained inactive.